International Assets Investment Management LLC Invests $185,000 in Bausch Health Companies Inc. (NYSE:BHC)

International Assets Investment Management LLC bought a new position in Bausch Health Companies Inc. (NYSE:BHC) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 23,058 shares of the company’s stock, valued at approximately $185,000.

Other institutional investors also recently bought and sold shares of the company. Ausdal Financial Partners Inc. bought a new position in Bausch Health Companies in the 3rd quarter worth $86,000. Jump Financial LLC bought a new position in Bausch Health Companies in the 3rd quarter worth $92,000. Mitsubishi UFJ Trust & Banking Corp bought a new position in Bausch Health Companies in the 3rd quarter worth $103,000. Park Avenue Securities LLC bought a new position in Bausch Health Companies in the 3rd quarter worth $169,000. Finally, Pathstone Family Office LLC bought a new position in Bausch Health Companies in the 3rd quarter worth $169,000. 78.65% of the stock is owned by institutional investors.

Bausch Health Companies Stock Up 1.0 %

Shares of Bausch Health Companies stock opened at $8.71 on Monday. The stock’s 50-day simple moving average is $9.30 and its 200-day simple moving average is $8.18. Bausch Health Companies Inc. has a 52 week low of $5.57 and a 52 week high of $11.46. The company has a market capitalization of $3.18 billion, a price-to-earnings ratio of -5.38 and a beta of 0.85.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings data on Thursday, February 22nd. The company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.01 by $0.14. Bausch Health Companies had a positive return on equity of 5,147.48% and a negative net margin of 6.76%. The business had revenue of $2.41 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the previous year, the business earned $1.02 earnings per share. The business’s revenue was up 9.8% on a year-over-year basis. On average, equities analysts expect that Bausch Health Companies Inc. will post 3.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on BHC shares. Jefferies Financial Group decreased their target price on Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, February 20th. StockNews.com raised Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Wednesday, February 7th. Finally, Royal Bank of Canada lowered their price objective on Bausch Health Companies from $12.00 to $11.00 and set a “sector perform” rating on the stock in a research report on Tuesday, April 23rd.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.